Trial ID or NCT#
NCT01525589
Status
Purpose
A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) expression profile in tumor samples.
Official Title
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Eligibility Criteria
Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Investigator(s)
Melinda L. Telli, M.D.
Medical oncologist,
Breast specialist
Associate Professor of Medicine (Oncology)
Allison W. Kurian, M.D., M.Sc.
Medical oncologist,
Breast specialist,
Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Contact us to find out if this trial is right for you.
CONTACT
CCTO
(650) 498-7061
View on ClinicalTrials.gov